Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (C...
Guardado en:
Autores principales: | Carlo Perricone, Elena Bartoloni, Roberto Gerli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Impact of colchicine on mortality in patients with COVID-19: A meta-analysis
por: Dimitrios A. Vrachatis, et al.
Publicado: (2021) -
COVID-19 – rheumatic diseases and rheumatologists
por: Maria Maślińska
Publicado: (2021) -
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
por: Dimitrios A. Vrachatis, et al.
Publicado: (2021) -
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity
por: Marilia Barreca, et al.
Publicado: (2021) -
Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases
por: Lakshmanan Suresh
Publicado: (2021)